Peptide basics

Neither has a registered trial, and one nearly got a disambiguation page

This page reports what public evidence exists for two peptides associated with sleep and mood. The answer is very little for both. Nothing here is a recommendation and no dose, schedule or route appears.

What the record holds

For both compounds the registered trial count is zero. There is no phase, no enrolment, and no posted result for either.¹²

The literature is small: 19 indexed publications for selank and 11 for DSIP over ten years. For comparison, MGF has 772 and LL-37 has 1,380, both also with zero or near-zero trials.¹²

Selank's Russian clinical history

Selank, like semax, comes from a Russian research programme with clinical work published in Russian-language journals. That work is largely absent from the databases used here.¹

So its zero describes the record we can check rather than everything ever done. That distinction is stated on its page, and it does not convert an unverifiable literature into evidence a reader can use.¹

How DSIP's number went wrong

Readership on this site comes from matching a compound to a Wikipedia article and reading its traffic. DSIP is an abbreviation, and the match landed on a disambiguation page — a page listing several unrelated meanings of the same letters.³

The traffic to that page was published as the compound's readership. It was not wrong about the traffic; it was wrong about what the traffic measured. A subject-match check now runs before any article's views are attributed to a compound.³

What to make of both

The honest summary is short. No registered human trial exists for either compound in the databases most of the world's medicine relies on, no regulator has approved either, and both are read about by thousands of people a month.¹²³

Common questions